Welcome to our dedicated page for ZyVersa Therapeutics news (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics stock.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical-stage specialty biopharmaceutical company committed to developing first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. Leveraging advanced proprietary technologies, ZyVersa is focused on creating therapeutic solutions that address these critical health challenges.
ZyVersa's impressive pipeline features two main drug development platforms. The Cholesterol Efflux Mediator™ VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for treating kidney diseases caused by lipid accumulation. Clinical trials for VAR 200 have shown promising results in animal models of diabetic kidney disease, focal segmental glomerulosclerosis (FSGS), and Alport syndrome (AS). The Phase 2a clinical trial protocol for diabetic kidney disease has recently received IRB approval, marking a significant milestone in the drug's development.
The second platform is the Inflammasome ASC Inhibitor IC 100, a novel humanized IgG4 monoclonal antibody. IC 100 inhibits the inflammasome adaptor protein ASC, which plays a crucial role in the body's inflammatory response. The drug is in preclinical development for treating various inflammatory conditions, including neurological diseases like Alzheimer's, multiple sclerosis, and traumatic brain injury. Recent research has highlighted IC 100's potential in addressing obesity-related inflammation and metabolic complications, further expanding its therapeutic scope.
Under the leadership of an experienced team with over 15 years of success in the biopharmaceutical industry, ZyVersa continues to advance its drug candidates towards clinical trials. The company's strategic partnerships and collaborations with notable research institutions like the University of Miami Miller School of Medicine further bolster its research and development efforts.
Financially, ZyVersa is navigating the challenges of a clinical-stage biopharmaceutical company. While the company reported a net loss of $98.3 million for the year ending December 31, 2023, it continues to secure funding through public and private equity, grants, and collaborations. Recent financial updates indicate a net loss improvement for Q1 2024, with operating expenses managed efficiently to support ongoing and future clinical trials.
For more detailed information, visit the ZyVersa Therapeutics website and stay updated with their latest news and developments.
ZyVersa Therapeutics (Nasdaq: ZVSA) has published a review article in Frontiers in Pharmacology discussing the NLRP3 inflammasome pathway as a potential target for treating mild cognitive impairment and Alzheimer’s disease. The paper outlines significant findings, including elevated IL-1β levels in Alzheimer's patients and positive results from anti-ASC antibody trials in animal models. The authors emphasize that treatments targeting the NLRP3 pathway may help reduce cognitive decline and Alzheimer's pathology. Co-founder Stephen C. Glover highlighted the urgent need for effective therapies to address cognitive impairment. ZyVersa is developing IC 100, a monoclonal antibody aimed at inhibiting this inflammasome pathway to mitigate inflammation-related damage in the central nervous system.
ZyVersa Therapeutics (Nasdaq: ZVSA) announced that CEO Stephen C. Glover will participate in a live interview on Benzinga All Access on April 18, 2023, at 11:10 AM EDT. The discussion will focus on the development progress of the company’s Cholesterol Efflux Mediator™ VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for CNS and non-CNS inflammatory diseases. Glover expressed enthusiasm for sharing ZyVersa's advancements in addressing unmet medical needs within its pipeline, particularly for kidney and inflammatory diseases. If you miss the live session, an archived version will be accessible online after the interview. For further details about ZyVersa and its proprietary technologies, visit their official website.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a biopharmaceutical company, has announced that CEO Stephen C. Glover will present at the Planet MicroCap Showcase 2023 in Las Vegas. The event is scheduled for April 26, 2023, at 2:00 PM PDT at Horseshoe Hotel & Casino. Glover will discuss the development of two key product candidates: Cholesterol Efflux Mediator™ VAR 200, aimed at addressing renal diseases, and Inflammasome ASC Inhibitor IC 100, targeting various CNS and inflammatory diseases. ZyVersa is focused on creating first-in-class therapies for unmet medical needs in renal and inflammatory diseases. Stakeholders are encouraged to schedule one-on-one meetings with Glover through the conference portal to learn more about the company’s innovative pipeline.
ZyVersa Therapeutics (NASDAQ: ZVSA) announced a significant scientific publication in the peer-reviewed journal Brain Pathology, focusing on the inflammasome ASC Inhibitor IC 100. This research, conducted by experts from the University of Miami, indicates that increased expression of inflammasome proteins like NLRP1 and NLRP3 occurs early in Alzheimer's disease (AD). The findings suggest that IC 100 could serve as a diagnostic tool and an early therapeutic intervention for AD by identifying neurons affected by the disease.
The study highlights the correlation between ASC expression and biomarkers of AD progression (Aβ and p-tau). ZyVersa's preclinical data indicate that IC 100 may alleviate chronic neuroinflammation, which plays a crucial role in AD progression.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced a significant corporate update, following its business combination with Larkspur Health Acquisition Corp. in December 2022. The company has initiated trading on Nasdaq and is advancing its lead clinical candidate, Cholesterol Efflux Mediator™ VAR 200, with an investigator-initiated trial planned for FSGS and other renal indications in Q4 2023. ZyVersa also prepares for an IND submission for inflammasome ASC inhibitor IC 100 in Q2 2024, supported by recent promising preclinical data. Despite not generating revenue since inception, the firm anticipates 2023 will be pivotal for growth.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced the grant of inducement equity awards to two newly hired employees, effective March 8, 2023. The grants comprise nonqualified stock options to purchase a total of 13,000 shares at an exercise price of $2.26 per share, aligning with the closing price on that date. These options will vest in three annual installments starting March 8, 2024, contingent upon continued employment. ZyVersa focuses on developing first-in-class drugs for renal and inflammatory diseases, with products like VAR 200 targeting rare kidney diseases. The company emphasizes a commitment to addressing significant unmet medical needs.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) has announced the addition of Dr. Richard J. Glassock to its Renal Scientific Advisory Board, enhancing its commitment to developing innovative treatments for renal diseases. Dr. Glassock, an expert in glomerular disease, joins a team of distinguished advisors to advance the clinical development of VAR 200, a phase 2a-ready drug aimed at reducing renal lipid accumulation. The drug targets orphan kidney diseases, including focal segmental glomerulosclerosis (FSGS) and has shown promise in preclinical studies. ZyVersa aims to leverage this expertise to enhance its drug therapies for significant unmet medical needs in renal and inflammatory diseases.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced that CEO Stephen C. Glover will speak at the 33rd Annual Oppenheimer Healthcare Conference held virtually from March 13-15, 2023. During the event, Glover will discuss the development status of their Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, aimed at treating renal diseases, and the inflammasome ASC inhibitor IC 100, targeting various CNS and inflammatory diseases. The conference aims to showcase ZyVersa's innovative product pipeline and potential for stockholder value. To learn more, a virtual one-on-one meeting with Glover can be arranged via the conference portal.
ZyVersa Therapeutics announced that CEO Stephen C. Glover will present key updates on its drug candidates during a fireside chat at the 35th Annual Roth Conference on March 14, 2023. The discussion will focus on the Cholesterol Efflux Mediator™ VAR 200, aimed at treating renal diseases, and the inflammasome ASC inhibitor IC 100, which targets various inflammatory diseases. The event will take place at The Ritz Carlton, Laguna Niguel, California.
ZyVersa, listed on Nasdaq as ZVSA, specializes in developing innovative therapies for conditions with significant unmet medical needs.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) recently highlighted research published in Translational Research, revealing that traumatic brain injury (TBI) enhances inflammasome activation in Alzheimer's disease (AD), worsening cognitive outcomes. It notes that individuals with a history of moderate TBI are 2.3 times more likely to develop AD, according to CDC data. The study asserts that IC 100, an inflammasome ASC inhibitor, significantly reduces this inflammatory response in AD models post-TBI. ZyVersa aims to leverage this data to advance its therapeutic approach targeting inflammasome-related neurological disorders.
FAQ
What is the current stock price of ZyVersa Therapeutics (ZVSA)?
What is the market cap of ZyVersa Therapeutics (ZVSA)?
What is ZyVersa Therapeutics, Inc.?
What are ZyVersa's main drug platforms?
What is the status of the VAR 200 clinical trials?
What conditions does IC 100 target?
Who are ZyVersa's research partners?
What recent financial updates has ZyVersa reported?
What technologies does ZyVersa utilize in its drug development?
How does IC 100 function?
What is the significance of the recent IRB approval for VAR 200?
Where can I find more information about ZyVersa?
